Clinical Distribution and Drug Susceptibility Characterization of Invasive Isolates in a Tertiary Hospital of Xinjiang Province.

Objective: This study aims to investigate the clinical distribution characteristics and drug susceptibility profiles of invasive isolates in a tertiary hospital in Urumqi.

Methods: The examination was conducted on samples obtained from patients who were clinically diagnosed with invasive candidiasis in this hospital. A total of 109 strains of strains were identified through the use of internal transcribed spacer (ITS) sequencing and fungal cultivation methods.

Retrospective Analysis of Tinea Capitis in Xinjiang, China.

Tinea capitis is a cutaneous infection of dermatophytes and predominant in children. It is one of common infectious diseases of children in Xinjiang, particularly in the southern Xinjiang. The aim of this study is to analyze the clinical and mycological characteristics of patients with tinea capitis in Xinjiang China.

Characterisation of a clinical isolated strain using a infection model.

Background: In recent years, the number of invasive aspergillus infection cases caused by () has gradually increased and this fungus is usually difficult to distinguish from in morphology. All of these presents a great challenge to the treatment of invasive fungal infections caused by . The present study aims to discuss the antifungal resistance, virulence and inflammatory factors' changes after the infection of larvae of separated from patients with chronic obstructive pulmonary disease (COPD) to reflect the host immune response.

Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.

Aspergillus species are the most common causative agents involved in otomycosis. In this study, 45 Aspergillus isolates were obtained from patients with otomycosis in western China during 2013-2016. The aim of this study is to identify the Aspergillus isolates to the species level by using β-tubulin gene sequencing and to evaluate their in vitro susceptibility to nine antifungal drugs: amphotericin B, itraconazole, voriconazole, posaconazole, ravuconazole, isavuconazole, caspofungin, micafungin and anidulafungin according to CLSI M38-A2.